0001209191-21-009119.txt : 20210209
0001209191-21-009119.hdr.sgml : 20210209
20210209211848
ACCESSION NUMBER: 0001209191-21-009119
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210205
FILED AS OF DATE: 20210209
DATE AS OF CHANGE: 20210209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Grigoriadis Dimitri E.
CENTRAL INDEX KEY: 0001423838
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 21608871
MAIL ADDRESS:
STREET 1: 12790 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-05
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001423838
Grigoriadis Dimitri E.
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Research Officer
Common Stock
2021-02-05
4
S
0
605
113.7563
D
82169
D
Common Stock
2021-02-08
4
S
0
687
116.6693
D
83456
D
Common Stock
2021-02-08
4
S
0
803
116.6938
D
84178
D
Common Stock
2021-02-08
4
S
0
1218
116.7014
D
85273
D
Stock Option
117.63
2021-02-08
4
A
0
38256
0.00
A
2031-02-08
Common Stock
38256
38256
D
Restricted Stock Unit
2021-02-08
4
A
0
6376
0.00
A
Common Stock
6376
6376
D
Sale of 605 shares of common stock issued upon vesting of 1,150 restricted stock units on February 5, 2021 to cover payroll and withholding taxes, with the balance of the shares (545) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $111.81 to $116.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Sale of 687 shares of common stock issued upon vesting of 1,974 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,287) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.97 to $117.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Sale of 803 shares of common stock issued upon vesting of 1,525 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (722) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $117.71. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Sale of 1,218 shares of common stock issued upon vesting of 2,313 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,095) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $117.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025.
/s/ Darin Lippoldt, Attorney-in-Fact
2021-02-09